Study shows early-life NuA4 complex inhibition programs lifelong proteostasis and longevity in C. elegans

Transient reduction of the NuA4 acetyltransferase complex during early development triggers a compensatory endoplasmic reticulum stress response and oleic acid accumulation, conferring lifelong resilience against proteotoxic stress and extending lifespan in C. elegans.

Researchers conducted a parental RNAi screen targeting 1,059 early-life genes in a C. elegans model expressing human Aβ 1-42.

The screen identified that transient reduction of the NuA4 acetyltransferase complex (by targeting the core catalytic subunit mys-1) during development—specifically before the L2 larval stage—attenuated Aβ- and α-synuclein-induced proteotoxicity and extended lifespan.

Conversely, knockdown of NuA4 subunits in later life exacerbated paralysis and shortened lifespan, highlighting a strict early-life window of opportunity.

The protective mechanism operates through a chromatin-ER-lipid axis: early-life reduction of NuA4-mediated H4K16ac triggers compensatory, early-life-biased activation of the UPRER transcription factor XBP-1.

Sustained XBP-1 activation remodels ER morphology and reprograms lipid metabolism via SBP-1/MDT-15, causing selective accumulation of oleic acid during development.

The resulting oleic acid pool must be actively mobilized via lipolysis (by lipases ATGL-1 and HOSL-1) in adulthood to confer long-lasting proteostasis resilience.

These findings expand the Developmental Origin of Health and Diseases (DOHaD) paradigm, demonstrating that developmental pathways can be actively programmed to establish late-life resilience against proteotoxicity.

The study reveals a novel mechanistic connection between histone H4K16 acetylation and the regulation of endoplasmic reticulum proteostasis.

The requirement of active lipase mobilization highlights that functional utilization and lipid turnover, rather than static storage of monounsaturated fatty acids like oleic acid, are crucial for proteostatic protection.

This basic research validates the therapeutic relevance of chromatin-remodeling, UPRER, and lipid mobilization pathways in mitigating proteotoxicity associated with Alzheimer's and Parkinson's diseases.

The critical developmental timing of this mechanism contrasts with the primary focus of active neurodegeneration pipelines, which typically target established proteotoxic damage in adult and symptomatic stages.

The findings encourage further pre-clinical investigation into monounsaturated fatty acid supplementation and epigenetic interventions to prophylactically promote healthy aging.

Preclinical studies evaluating whether transient, early-life epigenetic or dietary interventions (such as oleic acid supplementation) can program long-term proteostatic resilience and slow cognitive decline in mammalian models of neurodegenerative disease.